In a laboratory at the University of California, Davis, a team of chemists did something small. Impossibly small, in fact. Two atoms inside a well-known molecule got their positions swapped. On paper, it barely looked like a change at all. Same molecule, same weight, same overall shape. And yet, what came out the other side was something entirely new, a compound that no one had seen before, with properties that researchers are now calling some of the most promising in the history of neuropsychiatry.

For now, call it JRT. What it can do and what it might mean for millions of people living with conditions that medicine has failed to fix is worth sitting with for a moment before getting into the details.

What Went Wrong With Mental Health Treatment

Before getting to JRT, it helps to understand why so many people with serious mental illness are still struggling despite decades of drug development.

Conditions like schizophrenia, major depression, and addiction share something beneath the surface. In each of them, the physical structure of the brain changes. Specifically, tiny connectors between brain cells called dendritic spines and synapses shrink, weaken, or disappear entirely, especially in the prefrontal cortex. Chronic stress speeds up that damage. So do certain illnesses.

Current drugs mostly work by adjusting the chemical signals that travel between those brain cells. Antidepressants tweak serotonin. Antipsychotics block dopamine. What they do not do, which almost nothing does, is fix the structural damage itself. Patients often see partial relief of some symptoms while others, like the inability to feel pleasure, cognitive fog, and social withdrawal, remain stubbornly out of reach.

Psychedelics, oddly enough, can fix that structural damage. Compounds like LSD have a rare ability to actually regrow those lost connections, prompting the brain to sprout new dendritic spines and rebuild synaptic density. Researchers have known about this for years. But there has always been an obvious problem.

The Problem With Using LSD as Medicine

“No one really wants to give a hallucinogenic molecule like LSD to a patient with schizophrenia,” said David Olson, director of UC Davis’s Institute for Psychedelics and Neurotherapeutics.

Olson is not being glib. For patients with schizophrenia or a family history of psychosis, hallucinogens are outright dangerous. Hallucinations and psychotic episodes are already symptoms that these patients live with. Adding a powerful psychedelic into that picture is not a calculated risk; it is a non-starter. Which means the very patients who might benefit most from LSD’s brain-repair properties were always the ones who could never receive it.

For years, that felt like a dead end. LSD’s healing power and its hallucinogenic effects seemed bundled together, inseparable at the molecular level. To get one, you had to accept the other. Olson’s team decided to find out whether that was actually true.

Two Atoms, Five Years, One New Compound

What followed was not a happy accident. It took Olson’s team nearly five years to complete a 12-step chemical process to produce a new molecule. Along the way, two graduate students, Jeremy R. Tuck and Lee E. Dunlap, led much of the hands-on synthesis work. JRT gets its name from Jeremy R. Tuck, who was the first to successfully make it.

“Basically, what we did here is a tire rotation,” Olson said, describing the core change his team made. By moving just two atoms within LSD’s molecular structure, they created what chemists call a constitutional isomer, a molecule with identical parts, rearranged. Same atoms. Different address.

That shift changed which part of the brain’s serotonin receptor the molecule could interact with. Without getting too deep into the chemistry, LSD forms a small but consequential hydrogen bond at a specific point inside the receptor. JRT cannot form that bond. And losing that bond, it turns out, is precisely what separates a healing drug from a hallucinogenic one.

What JRT Does to the Brain

When researchers tested JRT in mice and in lab-grown brain cells, the results got attention fast. A single dose of JRT increased dendritic spine density in the prefrontal cortex by 46% and raised synapse density by 18%. In mice that had experienced chronic stress, which had caused visible cortical atrophy, one dose of JRT completely reversed the damage within 24 hours. Neurons that had shriveled under weeks of stress grew back. Connections that had been lost came back online.

Measured against ketamine, which is currently the fastest-acting antidepressant available and considered a benchmark in the field, JRT was roughly 100 times more potent as an antidepressant in preclinical testing at a fraction of the dose. Mice that had lost their preference for sweet food due to stress (a standard proxy for anhedonia, the inability to feel pleasure) regained it after JRT treatment. Cognitive flexibility tests, which measured whether stressed mice could adapt to new rules in a learning task, showed similar rescue effects. None of that is what makes JRT truly different, though. What sets it apart is what it did not do.

What JRT Did Not Do

JRT did not trigger hallucination-like behavior in mice. It did not produce gene expression patterns associated with schizophrenia. It did not worsen psychosis-linked behaviors. In fact, when mice were given LSD and JRT at the same time, JRT blocked the hallucination-like effects that LSD normally causes.

It also sidestepped most of the side effects tied to existing antipsychotic medications. Drugs like haloperidol work partly by blocking dopamine receptors, which is effective against hallucinations and delusions but often leads to stiff muscles, emotional blunting, and movement disorders. Clozapine, considered the most effective antipsychotic currently available, works more broadly but brings serious risks, including weight gain, metabolic problems, and sedation, which is why doctors tend to reserve it for patients who have not responded to anything else.

JRT showed no affinity for dopamine receptors, histamine receptors, or adrenergic receptors, the targets responsible for most of those side effects. It works through serotonin receptors, and even then, it works selectively, in a way that separates healing from hallucination.

“JRT has extremely high therapeutic potential,” Olson said. “Right now, we are testing it in other disease models, improving its synthesis, and creating new analogues of JRT that might be even better.”

Why Schizophrenia Patients Have the Most to Gain

Schizophrenia affects roughly half a percent of people worldwide, but that number understates the scale of disruption it causes in patients’ lives. Positive symptoms, such as hallucinations, delusions, and disorganized thinking, tend to get the most attention because they are dramatic and visible. Existing medications do a reasonable job of controlling them.

Negative and cognitive symptoms are a different story. Anhedonia. Avolition is a kind of profound motivational blankness where even small tasks feel insurmountable. Working memory problems. Difficulty with attention. Current antipsychotics offer little to no relief for these aspects of the disease, and many doctors and patients consider them the harder burden to carry long-term.

JRT, in preclinical testing, addressed exactly those harder symptoms. It improved cognitive flexibility. It rescued anhedonia. It rebuilt the cortical connections that negative and cognitive symptoms are believed to stem from. And it did all of it without touching the positive symptoms in the wrong direction, without making hallucinations or psychosis worse.

Whether those effects will translate to humans is still unknown. Every result reported so far comes from mice and rats, from lab cultures, from preclinical assays. Human clinical trials have not begun. Olson’s team continues refining the synthesis process and testing JRT against other neuropsychiatric and neurodegenerative diseases. One flag that researchers will need to watch: JRT shows partial activity at a receptor type called 5-HT2B, and sustained stimulation of that receptor has been linked to cardiac valve problems in previous drugs. That does not make JRT dangerous at this stage, but it is something that future studies will need to monitor carefully.

A New Way of Thinking About Psychedelics

JRT is part of something larger than one drug or one disease. For decades, psychedelics sat in a strange position in medicine, too politically fraught to study seriously, too chemically interesting to ignore entirely. In recent years, that changed. Psilocybin trials for depression have generated real clinical data. Ketamine got FDA approval. MDMA-assisted therapy moved through late-stage trials.

But all of those therapies still require the psychedelic experience itself. Patients take a dose, sit with a therapist for hours, and process whatever arises. That model works for some people. It does not work for patients with psychosis. And even for patients without psychosis, the logistics are demanding, the access is limited, and the stigma is real.

JRT suggests a different path: take the biology of what psychedelics do to the brain, strip away the experience entirely, and deliver the repair without the journey. A pill, rather than a session. A medicine, rather than a ceremony.

Olson has spent years making the case that psychedelics should be seen as chemical starting points, raw material for rational drug design, rather than as treatments in their own right. JRT is the strongest evidence yet that he may be right.

What It Means to Be a Mind That Can Heal Itself

For most of human history, serious mental illness looked like a permanent condition. You managed it, suppressed it, or lived around it. Few people talked about fixing it at the structural level because no one believed the structure could be changed without consequences too steep to accept. JRT asks whether that assumption was ever true, or whether we simply lacked the right tool.

If a brain that has been worn down by chronic stress or illness can rebuild its own connections after a single dose of something derived from LSD, if those lost synapses can actually come back, that changes what we are willing to believe about recovery. It changes how we think about the people who have not responded to anything available yet. And it raises a question worth sitting with: how many conditions have we labeled as permanent when what we really meant was that we had not yet found the right two atoms to move?

Human beings push at limits not because pushing always works, but because the limits keep turning out to be smaller than they looked. Sometimes the boundary between a psychedelic and a medicine is exactly two atoms wide.

Loading...